Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
28 hedge funds and large institutions have $26.7M invested in Provention Bio, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 6 closing their positions.
1,654% more capital invested
Capital invested by funds: $1.52M → $26.7M (+$25.2M)
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
155% more funds holding
Funds holding: 11 → 28 (+17)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.14M |
| 2 |
BlackRock
New York
|
+$1.64M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$924K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$867K |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$131K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 3 |
Goldman Sachs
New York
|
-$36K |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$30K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
PRVB Hedge Fund Activity: Q2 2019 in Review
28 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q2 2019, worth a combined $26.7M — up 1,654% from $1.52M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PRVB positions and 6 closed out — a net gain of 17 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.14M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $131K sold.
- 28 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q2 2019, up from 11 in Q1 2019.
- Funds reported $26.7M of Provention Bio, Inc. Common Stock stock for Q2 2019, up 1,654% quarter-over-quarter.
- 23 funds opened new Provention Bio, Inc. Common Stock positions in Q2 2019 and 6 closed out, a net change of +17 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q2 2019 was Vanguard Group, an estimated $2.14M added.
- The largest Provention Bio, Inc. Common Stock seller in Q2 2019 was Point72 Asset Management, an estimated $131K sold.
Based on aggregated 13F filings for Q2 2019.